Global X Management Co. LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.6% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 144,209 shares of the company’s stock after selling 10,227 shares during the period. Global X Management Co. LLC’s holdings in Novo Nordisk A/S were worth $5,998,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Jennison Associates LLC boosted its stake in shares of Novo Nordisk A/S by 16.4% in the second quarter. Jennison Associates LLC now owns 17,400,801 shares of the company’s stock worth $935,815,000 after buying an additional 2,452,120 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Novo Nordisk A/S by 6.3% in the second quarter. Loomis Sayles & Co. L P now owns 11,847,603 shares of the company’s stock valued at $637,164,000 after buying an additional 705,851 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Novo Nordisk A/S by 124.1% in the third quarter. JPMorgan Chase & Co. now owns 1,156,876 shares of the company’s stock valued at $48,115,000 after buying an additional 640,540 shares during the period. WCM Investment Management CA boosted its stake in shares of Novo Nordisk A/S by 5.2% in the third quarter. WCM Investment Management CA now owns 9,238,271 shares of the company’s stock valued at $384,220,000 after buying an additional 458,749 shares during the period. Finally, Saratoga Research & Investment Management boosted its stake in shares of Novo Nordisk A/S by 50.3% in the third quarter. Saratoga Research & Investment Management now owns 1,198,699 shares of the company’s stock valued at $49,854,000 after buying an additional 401,267 shares during the period. Institutional investors and hedge funds own 7.34% of the company’s stock.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) traded up 2.69% during trading on Wednesday, reaching $33.60. The company’s stock had a trading volume of 8,014,022 shares. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $59.00. The stock’s 50 day moving average is $36.32 and its 200-day moving average is $47.04. The firm has a market cap of $84.89 billion, a P/E ratio of 16.03 and a beta of 0.84.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Position Decreased by Global X Management Co. LLC” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/30/novo-nordisk-as-nvo-position-decreased-by-global-x-management-co-llc.html.

NVO has been the topic of several research reports. Citigroup Inc. reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Bank of America Corp. cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, August 8th. HSBC upgraded shares of Novo Nordisk A/S from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 31st. Morgan Stanley cut shares of Novo Nordisk A/S from an “overweight” rating to an “equal weight” rating in a research report on Thursday, September 1st. Finally, Zacks Investment Research cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, September 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $61.33.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.